OC12 | RISK OF VENOUS THROMBOEMBOLISM AFTER REMOVAL OF AN UPPER EXTREMITY CENTRAL CATHETER ASSOCIATED WITH A DEEP VEIN THROMBOSIS IN CANCER PATIENTS
M. Sartori, A. Trentini, S. Cavara, E. Favaretto, M. Soldati, B. Cosmi | Angiology and Blood Coagulation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Background. Removal of a central venous catheter (CVC) is often considered when catheter-associated upper extremity deep vein thrombosis (DVT) is diagnosed, whereas guidelines suggest not removing the catheter as long as it is in use, functional, well-positioned with a proximal extremity at the right atrial superior vena cava junction, and non-infected. However, it is unknown what the best strategy is in cancer patients with CRT.
Aim. The goal is to evaluate the effectiveness of removal versus retention of the thrombosed catheter.
Methods. This was a prospective, single-center study. We enrolled 233 participants (age: 56.8±16.6y, female: 58.4%) with cancer (metastatic cancer: 39.1%) and CRT. The follow-up was 12 months and the primary endpoint was the composite measure of recurrent CRT and pulmonary embolism (PE).
Results. All the patients were treated with enoxaparin for 3 months, of whom 22 (9.4%) underwent CVC removal ≤7 days from the diagnosis, 44 (18.9%) underwent CVC removal between 8 and 30 days, and 116 (49.8%) underwent CVC removal >30 days. A new CVC was inserted in 56 patients (24%). During the follow-up, there were 1 PE (2.4/100 patient-years, 95% CI: 0.4-12.6) and 9 CRT (22.0/100 patient-years, 95% CI: 12.0-36.7) recurrences in patients that retained the CVC, no PE, and 2 upper extremity thrombosis recurrences (1.6/100 patient-years, 95% CI: 0.5-5.8) in patients that underwent CVC removal, and 2 PEs (4.9/100 patient-years, 95% CI: 1.4-16.1) and 17 CRT recurrences (41.4/100 patient-years, 95% CI: 27.8-56.6) in patients that underwent catheter removal and insertion of a new CVC. The insertion of a new CVC sharply increased the risk of VTE recurrences (HR 6.11, 95% CI: 2.96–12.6, p < 0.001).
Conclusions. The maintenance of the thrombosed catheter is justified and associated with less VTE risk than removing the thrombosed catheter and inserting a new one.
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Most read articles by the same author(s)
- Società Italiana di Emostasi e Trombosi, PO56 | EXTERNAL VALIDATION OF THE SAVED SCORE IN A CANADIAN REGIONAL CANCER CENTER COHORT: A REAL-WORLD ANALYSIS , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO05 | DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF NOVEL IMATINIB AND NILOTINIB ANALOGUES EXPRESSING ENHANCED ANTIPLATELET AND ANTICANCER ACTIVITIES , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, OC02 | INCIDENCE AND PREDICTORS OF ARTERIAL THROMBOSIS IN CANCER PATIENTS: RESULTS FROM THE PROSPECTIVE COMPASS-ARTERIAL CANCER ASSOCIATED THROMBOSIS (COMPASS-ARTECAT) STUDY , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO26 | OUTCOMES OF DIRECT ORAL ANTICOAGULANTS IN UNUSUAL-SITE THROMBOSIS: IMPACT OF ACTIVE CANCER , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, OC05 | TIME TO START OF ANTICOAGULANT THERAPY AND SURVIVAL OUTCOMES IN CANCER PATIENTS WITH PULMONARY EMBOLISM , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO06 | ACTIVATED PLATELETS INDUCE THE FORMATION OF NEUTROPHIL EXTRACELLULAR TRAPS VIA TOLL-LIKE RECEPTOR-4 AND P-SELECTIN GLYCOPROTEIN LIGAND-1 , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO58 | TACKLING THE AWARENESS GAP IN CANCER-ASSOCIATED THROMBOSIS: IMPACT OF A BRIEF EDUCATIONAL INTERVENTION IN PATIENTS WITH GYNECOLOGICAL CANCERS , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO18 | THE THROMBO-INFLAMMATION AXIS AS PREDICTOR OF TOXICITY IN PATIENTS TREATED WITH CAR-T CELLS , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO65 | OVARIC CANCER PRESENTING WITH COLD-AGGLUTININ MEDIATED HEMOLYTIC ANEMIA, PULMONARY THROMBOEMBOLISM AND DEEP VEIN THROMBOSIS , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO60 | VEXAS SYNDROME AS A NEW SEVERE THROMBOPHILIC CLONAL CONDITION: A SINGLE CENTRE EXPERIENCE , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
